Allergan special meeting could happen with or without Ackman's stake

Bill Ackman

Allergan ($AGN) had hoped that a lawsuit could potentially prevent Valeant's ($VRX) takeover partner--Bill Ackman, whose Pershing Square Capital Management is Allergan's leading shareholder--from contributing to the 25% investor support threshold needed to call a special meeting. But now, Reuters' sources say, Team Valeant has rallied support from shareholders holding 35% of the company, meaning the meeting--at which it hopes to overturn Allergan's board and strike its buyout defenses--could take place with or without Ackman's 9.7% stake. Report

Suggested Articles

Turns out Procter & Gamble didn’t want Pfizer’s consumer health unit after all. But it did want Merck KGaA’s.

Private equity firm, in exclusive talks with Sanofi, says it'll invest to pump up Zentiva into an "independent European generics leader."

With suitor Takeda circling Shire, the Dublin-based target has pulled off a deal of its own.